Given inter-individual variability in tolerability profiles, switching to an alternative GLP-1 RA may also represent a reasonable strategy
If North Carolina is able to get a good deal, I dont know why other states wouldnt be able to participate in that. States consider high costs, possible savings of covering weight-loss drugs for their workers In 2023, Connecticut enacted a law requiring Medicaid to cover obesity treatment services
But NaBPC157's effect could not be inhibited by L-NAME, even with a tenfold (100 vs
Its like a lot of other things can be going on why somebody has objective improvement in 6 months
Some of these include: Hypoglycemia (a blood sugar level thats too low) Allergic reactions Worsening of diabetic retinopathy (eye disease) Acute kidney injury Possible increased risk of pancreatic or thyroid cancer Interactions with other medications Because of the results of animal studies, there has been some concern that semaglutide, liraglutide, and other GLP-1 RAs might increase the risk of certain cancers, including thyroid cancer
Prescribing practices and indications are expanding rapidly, and therefore, we must be careful about our conclusions, Osborn said
